NCT01706588已完成2 期
Preliminary Evaluation of the Efficacy and Local Tolerability of Injectable Diclofenac at 5, 12.5, 25 and 50 mg/mL, Administered Locally Prior to Surgery for the Prevention of Post-operative Pain After Third Molar Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- Area Under the Curve (AUC) of the Pain Scores.
研究概览
简要总结
This is a prospective, randomised, double-blind, placebo-controlled, parallel group study in approximately 75 patients undergoing surgical removal of an impacted lower third molar.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Out-patients of either gender.
- •Patients aged ≥ 18 to ≤ 65 years old.
- •Subjects able and willing to give their written consent prior to inclusion in the study.
- •Female subjects of childbearing potential must (1) have a negative urine pregnancy test at the inclusion visit, (2) be using an appropriate method of contraception according to the definition of Note of ICH M3 Guideline (implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner), and (3) be willing to continue using the contraceptive method throughout the entire study period.
- •Subjects must (1) be able to comprehend the full nature and purpose of the study, including possible risks and side effects, (2) fully co-operate with the Investigator, (3) comply with the requirements of the entire study.
- •Patients undergoing surgical extraction of a single, fully or partially impacted mandibular 3rd molar requiring bone removal.
排除标准
- •Patients refusing to give written informed consent.
- •Patients not able to understand the purposes of the study or not willing to return for the control visits.
- •Patients with major psychiatric disorders that, in the investigator's opinion, could compromise study participation.
- •Patients enrolled in any clinical trial in the previous 3 months.
- •Employees of the study centre with direct involvement in the proposed study or other studies under the direction of the main investigator or study centre, as well as family members of the employees or investigator.
- •Pregnant or breast-feeding women.
- •Alcohol or drug abuse in the previous 12 months.
- •Clinically significant or unstable concomitant disease whose sequelae might interfere with the study evaluation parameters.
研究组 & 干预措施
Diclofenac sodium 5 mg/mL
Experimental
干预措施: Diclofenac sodium (Drug)
Diclofenac sodium 12.5 mg/mL
Experimental
干预措施: Diclofenac sodium (Drug)
Diclofenac sodium 25 mg/mL
Experimental
干预措施: Diclofenac sodium (Drug)
Diclofenac sodium 50 mg/mL
Experimental
干预措施: Diclofenac sodium (Drug)
Placebo 1 mL
Placebo Comparator
干预措施: Diclofenac sodium (Drug)
结局指标
主要结局
Area Under the Curve (AUC) of the Pain Scores.
时间窗: Pain scores will be measured over the time from end of surgery (time 0) to the 6 hour post-surgery
Pain will be scored by the patient at the end of surgery (time 0) and at 15-minute intervals after surgery for a total of 6 hours on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
次要结局
- Postsurgical Extra-oral Swelling(measured at 6 hours postsurgery, at day 3 and 1 week postsurgery)
- Trismus(measured at 6 hours postsurgery, at day 3 and 1 week postsurgery)
- Time to First Use of Rescue Medication.(measured from end of surgery up to 1 week postsurgery)
- Peak Pain Intensity(measured from end of surgery up to 12 hours postsurgery)
- Amount of Rescue Medication(consumed by the patient every 15-minutes postsurgery up to 6 hours postsurgery)
- Rescue Medication Consumption(consumed by the patient from end of surgery up to 24 and up to 48 hours postsurgery)
- Patient and Investigator Global Evaluation of the Effectiveness of Treatment(at 6 hour postsurgery and on Day 3)
- Time to Onset of Pain(measured from end of surgery up to 12 hours postsurgery)
- Vital Signs(presurgery (within 30 days from surgery), at day of surgery (day 1), day 3 and 1 week postsurgery.)
- Number of Patients With Adverse Events(from signature of the informed consent to 1 week postsurgery)
- Recurrent Bleeding(every hour up to 6 hour postsurgery)
- Wound Healing(at 6 hour postsurgery, and on day 3 and 1 week postsurgery)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung DiseaseCystic FibrosisNCT00103714Merck Sharp & Dohme LLC72
已完成
4 期
Long-term Study Of Ropinirole In Restless Legs SyndromeRestless Legs SyndromeNCT00329602GlaxoSmithKline404
已完成
2 期
Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women.Vasomotor SyndromeNCT06726850Changchun GeneScience Pharmaceutical Co., Ltd.129
已完成
3 期
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.AsthmaNCT01498679GlaxoSmithKline311
尚未招募
2 期
A Study of GM-XANTHO in Pressure Ulcer PatientsDiabetes MellitusPressure UlcerNCT05199077Xantho Biotechnology Co., LTD58